Assyro AI

FDA Orange Book · active-ingredient family

Gallium ga-68 edotreotide

Gallium ga-68 edotreotide is approved as 1 brand and 1 generic application in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.

1

Brand (NDA)

1

Generics (ANDA)

0

Listed patents

2

Exclusivity periods

Brand (NDA) products · solution

ProductApplicantApplicationTEApproved
GALLIUM GA 68 EDOTREOTIDERLDUIHC PET IMAGINGNDA 210828APAug 21, 2019

Generic (ANDA) products (1)

ProductApplicantApplicationTEApproved
GALLIUM GA 68 EDOTREOTIDEMETHODISTANDA 218845APOct 10, 2025

Marketing exclusivity (2)

  • ODE-383Orphan-drug exclusivity (7 years)

    Aug 21, 2026

    in 2 mo

  • WExclusivity withdrawal / change

    Aug 21, 2026

    in 2 mo

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Gallium ga-68 edotreotide — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.